Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis;Anti-TNF alpha dans le traitement de la polyarthrite rhumatoïde et de la spondylarthrite ankylosante

Presse Medicale

Volumn 38, Issue 5, 2009, Pages 774-787

  Lanfant Weybel, Karine ^a   Lequerré, Thierry ^a   Vittecoq, Olivier ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANKYLOSING SPONDYLITIS; CANCER RISK; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HUMAN; INFECTION; INFECTION RISK; LYMPHOMA; PRACTICE GUIDELINE; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SHORT SURVEY; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67349172679     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2009.02.003     Document Type: Short Survey

References (52)

1. Claudepierre P., Wendling D., and Cohen J.D. Anti-TNF alpha dans le traitement du rhumatisme psoriasique. Presse Med 35 (2006) 461-468
2. Brennan F.M., and McInnes I.B. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 118 (2008) 3537-3545
3. Braun J., Bollow M., Neure L., Seipelt E., Seyrekbasan F., Herbst H., et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38 (1995) 499-505
4. Pinals R.S., Masi A.T., and Larsen R.A. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 24 (1981) 1305-1315
5. Maniken H., Kautiainen H., Hannonen P., and Sokka T. Is DAS28 an appropriate toolto asses remission in rheumatoid arthritis ?. Ann Rheum Dis 64 (2005) 1389-1390
6. Van Der Heijde D., Dankert T., Nieman F., Rau R., and Boers M. Reliability and sensitivity to change of a simplification of the Sharp/van der Heijde radiological assesment in rheumatoid arthritis. Rheumatology 38 (1999) 941-947
7. Kremers H.M., Crowson C.S., Therneau T.M., Roger V.L., and Gabriel S.E. High 10-year cardiovascular risk in newly diagnosed rheumatoid arthritis 5RA) patients. Arthritis Rheum 56 (2007) S833
8. Lipsky P.E., Van Der Heijde D., St Clair W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343 (2000) 1594-1602
9. Van Der Heijde D., Klareskog L., Rodriguez-Valverde V., Codreanu C., Bolosiu H., Melo-Gomes J., et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis. Arthritis Rheum (2006) 1063-1074
10. Weinblatt M.E., Keystone E., Furst D., Moreland L.W., Weisman M.H., Birbara C.A., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The ARMADA trial. Arthritis Rheum 48 (2003) 35-45
11. St Clair E.W., Van Der Heijde D.M., Smolen J.S., Maini R.N., Bathon J.M., Emery P., et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis : a randomised controlled trial. Arthritis Rheum 50 (2004) 3432-3443
12. Emery P., Breedveld F.C., Hall S., Durez P., Chang D.J., Robertson D., et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET) : a randomised, double-blind, parallel treatment trial. Lancet 372 (2008) 375-382
13. Breedveld F.C., Weisman M.H., Kavanaugh A.F., Cohen S.B., Pavelka K., Van Vollenhoven R., et al. The PREMIER study : a multicenter, randomised, double blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, agressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54 (2006) 26-37
14. Davis Jr. J.C., Van Der Heijde D., Braun J., Dougados M., Cush J., Clegg D.O., et al., Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis : a randomized, controlled trial. Arthritis Rheum 48 (2003) 3230-3236
15. Van der Heijde D., Kivitz A., Schiff M.H., Sieper J., Dijkmans B.A., Braun J., et al., ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis : results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54 (2006) 2136-2146
16. van der Heijde D., Dijkmans B., Geusens P., Sieper J., DeWoody K., Williamson P., et al., Ankylosing spondylitis study for the evaluation of recombinant infliximab therapy study group. Efficacy and safety of infliximab in patients with ankylosing spondylitis : results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52 (2005) 582-591
17. van der Heijde D., Pangan A.L., Schiff M.H., Braun J., Borofsky M., Torre J., et al., ATLAS Study Group. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann Rheum Dis 67 (2008) 1218-1221
18. Baraliakos X., Davis J., Tsuji W., and Braun J. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 52 (2005) 1216-1223
19. Braun J., Landewé R., Hermann K.G., Han J., Yan S., Williamson P., et al., ASSERT Study Group. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab : results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 54 (2006) 1646-1652
20. Lambert R.G., Salonen D., Rahman P., Inman R.D., Wong R.L., Einstein S.G., et al. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis : a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 56 (2007) 4005-4014
21. Braun J., Deodhar A., Dijkmans B., Geusens P., Sieper J., Williamson P., et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Care & Research 59 (2008) 1270-1278
22. van der Heijde D., Schiff M.H., Sieper J., Kivitz A., Wong R.L., Kupper H., et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis (2008) 10.1136/ard.2007.087270
23. Davis Jr. J.C., van der Heijde D.M., Braun J., Dougados M., Clegg D.O., Kivitz A.J., et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 67 (2008) 346-352
24. Carmona L., Gómez-Reino J.J., and BIOBADASER Group. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 8 (2006) R72
25. Heiberg M.S., Koldingsnes W., Mikkelsen K., Rødevand E., Kaufmann C., Mowinckel P., et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis : results from a longitudinal, observational, multicenter study. Arthritis Rheum 59 (2008) 234-240
26. Breban M., Ravaud P., Claudepierre P., Baron G., Henry Y.D., Hudry C., et al. French ankylosing spondylitis infliximab network. Maintenance of infliximab treatment in ankylosing spondylitis : results of aone-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 58 (2008) 88-97
27. de Vries M.K., Wolbink G.J., Stapel S.O., de Vrieze H., van Denderen J.C., Dijkmans B.A., et al. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 66 (2007) 1252-1254
28. Vermeire S., Noman M., Van Assche G., Baert F., D'Haens G., and Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 56 (2007) 1226-1231
29. Braun J., Baraliakos X., Listing J., and Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 52 (2005) 2447-2451
30. Rudwaleit M., Rodevand E., Holck P., Vanhoof J., Kron M., Kary S., et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis : results of a prospective open-label study. Ann Rheum Dis (2008) 10.1136/ard.2008.092585
31. Braun J., Baraliakos X., Listing J., Davis J., van der Heijde D., Haibel H., et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor α agents. Arthritis Care & Research 57 (2007) 639-647
32. Maksymowych W.P., Chiowchanwisawakit P., Clare T., Pedersen S.J., Ostergaard M., and Lambert R.G. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis : Evidence of a relationship between inflammation and new bone formation. Arthritis Rheum 60 (2009) 93-102
33. van der Heijde D., Landewé R., Baraliakos X., Houben H., van Tubergen A., Williamson P., et al., Ankylosing Spondylitis study for the evaluation of recombinant infliximab therapy study group. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 58 (2008) 3063-3070
34. van der Heijde D., Landewé R., Einstein S., Ory P., Vosse D., Ni L., et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 58 (2008) 1324-1331
35. Pham T., Fautrel B., Dernis E., Goupille P., Guillemin F., Le Loët X., et al. Club Rhumatismes et Inflammation (CRI/SFR). Recommendations of the French society for rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis : 2007 update. Joint Bone Spine 74 (2007) 638-646
36. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Scwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001) 1098-1104
37. Mohan V.P., Scanga C.A., Yu K., Scott H.M., Tanaka K.E., Tsang E., et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis : possible role for limiting pathology. Infection and Immunity 69 (2001) 1847-1855
38. Tubach F, Salmon D, Ravaud P, Lequerré T, Goupille P, Shaeverbeke T et al. The risk of tuberculosis with anti-TNF is higher with monoclonal antibodies than with the soluble receptor. Results of the French 3-year prospective RATIO observatory. Ann Rheum Dis 2008; 67(Suppl II):52.(OP-0014).
39. Patients on anti-TNF have an increase risk of lymphoma compared with the general population. Results of the French 3-year prospective RATIO observatory. Ann Rheum Dis 2008; 67(Suppl II) :FRI0116.
40. Wolfe F., and Michaud K. Lymphoma in rheumatoid arthritis: the effects of methotrexate and anti tumor necrosis factor therapy in 18 572 patients. Arthritis Rheum 50 (2004) 1740-1751
41. Askling J, Raaschou P, van Vollenhoven R, Jacobsson L, Geborek P, Feltelius N et al. Anti-TNF therapy in RA and cancer risk: relation to duration of follow up, cumulative treatment and therapeutic response. Ann Rheum Dis 2008; 67(suppl.II) : OP-0013.
42. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., and Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systemic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006) 2275-2285
43. Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ et al. Etanercept therapy in rheumatoid arthritis and the risk of malignancies. Ann Rheum Dis 2008; 67(Suppl.II):OP-0012.
44. Wolfe F., and Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy. Analyses from a large US observational study. Arthritis Rheum 56 (2007) 2886-2895
45. Greenberg J., Strand V., Keystone E., Curtis J., Maury E., Reed G., et al. TNF inhibitors (TNF-I) and risk of malignancy in 8072 RA patients followed over 15495 patients years. Arthritis Rheum 56 Suppl (2007) S158
46. Pham T, Claudepierre P, Deprez X, Fautrel B, Goupille P, Hilliquin P et al. Traitements anti-TNFα et suivi de la tolérance: fiches pratiques élaborées par le Club rhumatisme et inflammation (CRI), section de la Société française de rhumatologie (SFR), Mise à jour 2008. Rev Rhum 2008 Hors série n°5.
47. Lequerré T., Gauthier-Jauneau A.C., Bansard C., Derambure C., Hiron M., Vittecoq O., et al. Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res Ther 8 (2006) R105-R115
48. Trocmé C., Marotte H., Baillet A., Pallot-Prades B., Garin J., Grange L., Miossec P., et al. Apolipoprotein A-I and platelet factor 4 are biomarkers for Infliximab response in rheumatoid arthritis. Ann Rheum Dis (2008) 10.1136/ard.2008.093153
49. Rudwaleit M., Listing J., Brandt J., Braun J., and Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 63 (2004) 665-670
50. Rudwaleit M., Schwarzlose S., Hilgert E.S., Listing J., Braun J., and Sieper J. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 67 (2008) 1276-1281
51. Keystone E., Heijde D., Mason Jr. D., Landewé R., Vollenhoven R.V., Combe B., et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis : findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 58 (2008) 3319-3329
52. Keystone E.C., Genovese M.C., Klareskog L., Hsia E.C., Hall S.T., Miranda P.C., et al. Golimumab, a human antibody to TNF-{alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate : The GO-FORWARD Study. Ann Rheum Dis (2008) 10.1136/ard.2008.099010